Provention Bio TZIELD FDA Approval Presentation November 2022

Loading viewer...

investor_presentation

Format: PDF investor_presentation

Provention Bio presents TZIELD, a breakthrough designated drug approved by the FDA for stage 2 type 1 diabetes (T1D), outlining commercialization plans and market opportunity. The presentation details the unmet need in T1D and Provention's strategy for bringing TZIELD to market in partnership with Sanofi.

Browse all investor_presentations →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Provention Bio, Inc.

View all →

Provention Bio 2022 Investor Presentation - Teplizumab Autoimmune

investor_presentation

32 Pages

Provention Bio Investor Presentation March 2022

investor_presentation

Similar investor_presentations from other companies

Browse all →

Sonida Senior Living Investor Presentation 2023

investor_presentation

13 Pages

Sonida Senior Living

TAAL Distributed Information Technologies Investor Presentation — March 2022

investor_presentation